Denmark becomes the first European country to permanently suspend usage of the Oxford–AstraZeneca COVID-19 vaccine, following weeks of reports that the vaccine may cause blood clots. The move is expected to delay the country's vaccination program by "several weeks".
Denmark becomes the first European nation to permanently halt the rollout of the Oxford–AstraZeneca COVID-19 vaccine candidate, following weeks of reports that the vaccine may in rare cases cause blood clots. The move is expected to delay the country's vaccination program by "several weeks".
Denmark becomes the first European nation to permanently halt the rollout of the Oxford–AstraZeneca COVID-19 vaccine candidate, following weeks of reports that the vaccine may in rare cases cause blood clots. The move is expected to delay the country's vaccination program by "several weeks".
Denmark becomes the first European country to permanently halt the rollout of the Oxford–AstraZeneca COVID-19 vaccine candidate, following weeks of reports that the vaccine may in rare cases cause blood clots. The move is expected to delay the country's vaccination program by "several weeks".
Denmark becomes the first European country to permanently suspend usage of the Oxford–AstraZeneca COVID-19 vaccine candidate, following weeks of reports that the vaccine may cause blood clots. The move is expected to delay the country's vaccination program by "several weeks".
Denmark becomes the first European country to permanently suspend usage of the Oxford–AstraZeneca COVID-19 vaccine, following weeks of reports that the vaccine may cause blood clots. The move is expected to delay the country's vaccination program by "several weeks".
